Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615693 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00615693 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 13 participants.
The verdict
NCT00615693, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.
Interventions
- DRUG AEB071
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615693
The ClinicalTrials.gov registry entry for NCT00615693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AEB071 is the first listed.
NCT00615693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615693 about?
NCT00615693 is a clinical study titled "Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis". The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.
What is the current status of trial NCT00615693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00615693?
The interventions under investigation include: AEB071 (DRUG).
Who is sponsoring clinical trial NCT00615693?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.